Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8789929 | Urologic Oncology: Seminars and Original Investigations | 2018 | 12 Pages |
Abstract
Our results underscore that exogenous FGF-2 can shape PCa cell genomes and that stromal FGF-2 expression is detectable in a sizeable proportion of advanced PCa where it is associated with adverse clinico-pathological features. Our results highlight the impact of the tumor stroma on malignant progression and provide a rationale for a further exploration of components of the tumor stroma as therapeutic targets in PCa.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Carine M.D., Aysenur M.D., Martina Heller, Michael Falkenstein, Adam Ph.D., Yanis Ph.D., Holger Ph.D., Carsten M.D., Esther M.D., Anette M.D., Glen M.D., Markus M.D., Nora M. M.D., Ph.D., Stefan M.D.,